- Home
- TURN vs APLT Comparison
TURN vs APLT Comparison
Compare TURN & APLT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TURN
- APLT
- Stock Information
- Founded
- TURN 1981
- APLT 2016
- Country
- TURN United States
- APLT United States
- Employees
- TURN N/A
- APLT N/A
- Industry
- TURN Finance/Investors Services
- APLT Biotechnology: Pharmaceutical Preparations
- Sector
- TURN Finance
- APLT Health Care
- Exchange
- TURN Nasdaq
- APLT Nasdaq
- Market Cap
- TURN 35.3M
- APLT 37.5M
- IPO Year
- TURN N/A
- APLT 2019
- Fundamental
- Price
- TURN $3.80
- APLT $0.37
- Analyst Decision
- TURN
- APLT Buy
- Analyst Count
- TURN 0
- APLT 7
- Target Price
- TURN N/A
- APLT $6.10
- AVG Volume (30 Days)
- TURN 43.7K
- APLT 2.3M
- Earning Date
- TURN 05-12-2025
- APLT 04-14-2025
- Dividend Yield
- TURN N/A
- APLT N/A
- EPS Growth
- TURN N/A
- APLT N/A
- EPS
- TURN N/A
- APLT N/A
- Revenue
- TURN $194,813.00
- APLT $455,000.00
- Revenue This Year
- TURN N/A
- APLT $3,031.87
- Revenue Next Year
- TURN N/A
- APLT $312.01
- P/E Ratio
- TURN N/A
- APLT N/A
- Revenue Growth
- TURN 254.25
- APLT N/A
- 52 Week Low
- TURN $3.12
- APLT $0.30
- 52 Week High
- TURN $4.20
- APLT $10.62
- Technical
- Relative Strength Index (RSI)
- TURN 51.81
- APLT 42.55
- Support Level
- TURN $3.59
- APLT $0.31
- Resistance Level
- TURN $3.94
- APLT $0.38
- Average True Range (ATR)
- TURN 0.34
- APLT 0.05
- MACD
- TURN 0.02
- APLT 0.00
- Stochastic Oscillator
- TURN 73.03
- APLT 48.39
About TURN 180 Degree Capital Corp.
180 Degree Capital Corp is active in the financial services domain. It is a non-diversified closed-end management investment company whose objective is to achieve long-term capital appreciation by making venture capital investments. It focuses its investments on companies commercializing and integrating products enabled by disruptive technologies mainly in the life sciences, precision medicine, and health industries.
About APLT Applied Therapeutics Inc.
Applied Therapeutics Inc is a clinical-stage biopharmaceutical company, developing a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need. The company's drug compounds pipeline includes, AT-007 which is a novel central nervous system, penetrant ARI that it is developing for the treatment of rare metabolic diseases, including Galactosemia and Sorbitol Dehydrogenase (SORD) Deficiency, AT-001 for the treatment of diabetic cardiomyopathy, and AT-003 for the treatment of diabetic retinopathy.